TRACON Pharmaceuticals (NASDAQ:TCON) Stock Passes Below 200-Day Moving Average of $1.95

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.95 and traded as low as $0.11. TRACON Pharmaceuticals shares last traded at $0.11, with a volume of 18,037 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. StockNews.com started coverage on TRACON Pharmaceuticals in a research note on Thursday. They issued a “hold” rating on the stock. HC Wainwright reiterated a “neutral” rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st.

TRACON Pharmaceuticals Stock Performance

The company has a fifty day simple moving average of $0.19 and a two-hundred day simple moving average of $1.89. The company has a market capitalization of $358,050.00, a price-to-earnings ratio of 0.16 and a beta of 1.35.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The business had revenue of $0.06 million during the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.